News | PET Imaging | August 02, 2016

PET Imaging Could Provide Helpful Information for Genetically Linked Lung Cancer

Big data may help determine best treatment, suggests large study

PET, positron emission tomography, genetically linked lung cancer, AAPM, big data

August 2, 2016 — A cutting-edge method of extracting big data from positron emission tomography (PET) images can provide additional information to quantify lung tumors caused by a genetic mutation. This information could help guide the most effective treatment, suggest findings of a study of nearly 350 patients being presented at the 58th Annual Meeting of the American Association of Physicists in Medicine (AAPM), July 31-Aug. 4 in Washington, D.C.

Advances in genomics – the analysis of an organism’s genetic information – have shown that non-small cell lung cancer (NSCLC), the most common type of lung cancer, often is caused by mutations in specific genes. These mutations include epidermal growth factor receptor (EGFR) and Kristen rat sarcoma viral (KRAS). For example, 15 percent of patients have EGFR mutations and often benefit from tyrosine kinase inhibitor (TKI) therapies. Therefore, identification of these mutations is crucial for selecting the most effective treatment for these patients. 

PET imaging often is used to assess tumor glucose metabolism and an essential tool for lung cancer management. Studies have shown that some of the biological and genetic variations within tumors potentially can be captured in PET images.

Using big data radiomics — extracting comprehensive information from PET images — researchers evaluated the associations between radiomic features of tumors and EGFR and KRAS mutations in about 350 NSCLC lung cancer patients. The mutations were confirmed by molecular testing based on biopsies of tumor tissues, the standard of care for mutation identification. Researchers found that radiomic features describing different aspects of the tumor, such as its shape and textures, appear to be associated with EGFR mutations. Their results suggest that different metabolic imaging patterns (or imaging phenotypes) that are quantified by radiomic features may be caused by EGFR mutations.

“Our long-term goal would be to use PET or another imaging technique to develop non-invasive imaging biomarkers that complement molecular tests,” said Hugo Aerts, Ph.D., director of the Computational Imaging and Bioinformatics Laboratory at Dana Farber Cancer Institute, Brigham and Women’s Hospital and Harvard Medical School in Boston.

“Medical images are regularly acquired for every cancer patient that comes into our clinic for treatment, which is the case at many other cancer centers as well,” said Stephen Yip, Ph.D., an instructor at Harvard Medical School, Dana Farber Cancer Institute and Brigham and Women’s Hospital. “This early research suggests that standard-of-care PET imaging may help guide doctors in identifying patients with EGFR mutations, potentially providing valuable information for personalized lung cancer therapy.”

“More research needs to be done to further understand the complementary role of PET imaging to molecular testing,” Aerts said.

The researchers are now assessing combining PET-based radiomic features with features derived from other imaging tests, such as computed tomography (CT) or magnetic resonance imaging (MRI), to improve the accuracy of genetic mutation identification in lung and brain cancers.

For more information: www.aapm.org

Related Content

Machine Learning IDs Markers to Help Predict Alzheimer's

Neurologists use structural and diffusion magnetic resonance imaging (MRI) to identify changes in brain tissue (both gray and white matter) that are characteristic of Alzheimer's disease and other forms of dementia. The MRI images are analyzed using morphometry and tractography techniques, which detect changes in the shape and dimensions of the brain and in the tissue microstructure, respectively. In this example, the images show the normal brain of an elderly patient. Image courtesy of Jiook Cha.

News | Neuro Imaging | September 20, 2018
New research has shown a combination of two different modes of magnetic resonance imaging (MRI), computer-based...
SimonMed Deploys ClearRead CT Enterprise Wide
News | Computer-Aided Detection Software | September 17, 2018
September 17, 2018 — National outpatient physician radiology group SimonMed Imaging has selected Riverain Technologie
Lightvision near-infrared fluorescence imaging system
News | Women's Health | September 11, 2018
Shimadzu Corp.
Veye Chest version 2
News | Lung Cancer | September 11, 2018
Aidence, an Amsterdam-based medical AI company, announced that Veye Chest version 2, a class IIa medical device, has
Videos | Radiation Therapy | September 07, 2018
A discussion with Ehsan Samei, Ph.D., DABR, FAAPM, FSPIE, director of the Duke University Clinical Imaging Physics Gr
The Siemens Biograph Vision PET-CT system was released in mid-2018.

The Siemens Biograph Vision PET-CT system was released in mid-2018.

Feature | Nuclear Imaging | September 07, 2018 | By Dave Fornell
Nuclear imaging technology for both single photon emission computed tomography (SPECT) and positron emission tomography...
PET Imaging Agent Predicts Brain Tau Pathology, Alzheimer's Diagnosis
News | PET Imaging | September 05, 2018
Eli Lilly and Co. and Avid Radiopharmaceuticals Inc. announced a Phase 3 study of positron emission tomography (PET)...
Check-Cap Announces Interim Results of European Study of C-Scan System Version 3
News | Colonoscopy Systems | September 04, 2018
Check-Cap Ltd. announced the interim results for its post-CE approval study of the C-Scan system Version 3, an...
Brain Iron Levels May Predict Multiple Sclerosis Disabilities
News | Neuro Imaging | August 31, 2018
A new, highly accurate magnetic resonance imaging (MRI) technique can monitor iron levels in the brains of multiple...
Study Finds Multiple Sclerosis Drug Slows Brain Shrinkage

An NIH-funded clinical trial suggested that the anti-inflammatory drug ibudilast may slow brain shrinkage caused by progressive MS. Image courtesy of Robert J. Fox, M.D., Cleveland Clinic.

News | Neuro Imaging | August 30, 2018
August 30, 2018 — Results from a clinical...